bluuebunny/crossref_metadata_2025_split huggingface dataset:
Drotrecogin Alfa
Authors: Cada Dennis J. , Levien Terri , Baker Danial E. 
Published: January 2018

Each month, subscribers to The Formulary® Monograph Service receive five to six well-documented monographs on drugs that are newly released or are in late Phase III trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and pharmacy/nursing in-ser-vices. A comprehensive target drug utilization evaluation (DUE) is also provided each month. The monographs are published in printed form and on diskettes that allow customization. Subscribers to the The Formulary Monograph Service also receive access to a pharmacy bulletin board, The Formulary Information Exchange (The F.I.X). All topics pertinent to clinical and hospital pharmacy are discussed on The F.I.X. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. If you would like information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800-322-4349. The May 2002 Formulary monograph topics are 90Y ibritumomab tiuxetan, inerferon beta-1a, tiotropium, rifaximin, and eplerenone. The DUE is on pegfilgrastim.
Anakinra
Authors: Cada Dennis J. , Levien Terri , Baker Danial E. 
Published: January 2018

Each month, subscribers to The Formulary® Monograph Service receive five to six well-documented monographs on drugs that are newly released or are in late Phase III trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation (DUE) is also provided each month. The monographs are published in printed form and on diskettes that allow customization. Subscribers to the The Formulary Monograph Service also receive access to a pharmacy bulletin board, The Formulary Information Exchange (The F.I.X). All topics pertinent to clinical and hospital pharmacy are discussed on The F.I.X. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. If you would like information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800-322-4349. The May 2002 Formulary monograph topics are 90Y ibritumomab tiuxetan, inerferon beta-1a, tiotropium, rifaximin, and eplerenone. The DUE is on pegfilgrastim.
Beware of Erroneous Daily Oral Methotrexate Dosing; Sound-Alike Names: Diprivan and Ditropan how Many Viokase? Indicate mEq of Potassium or Sodium when Phosphorous Supplements are Prescribed
Authors: Cohen Michael R. 
Published: January 2018

These medication errors have occurred in health care facilities at least once. They will happen again–perhaps where you work. Through education and alertness of personnel and procedural safeguards, they can be avoided. You should consider publishing accounts of errors in your newsletters and/or presenting them in your inservice training programs. Your assistance is required to continue this feature. The reports described here were received through the USP Medication Errors Reporting Program, which is presented in cooperation with the Institute for Safe Medication Practices. If you have encountered medication errors and would like to report them, you may call USP toll-free, 24 hours a day, at 800-233-7767 (800-23-ERROR). Any reports published by ISMP will be anonymous. Comments are also invited; the writers' names will be published if desired. ISMP may be contacted at the address shown below.
Fluoxetine: Raynaud's Phenomenon
Authors: Generali Joyce , Cada Dennis J. 
Published: January 2018

Off-Label Drug Uses This Hospital Pharmacy feature is extracted from Off-Label DrugFacts, a quarterly publication available from Facts and Comparisons. Off-Label DrugFacts is a practitioner-oriented resource for information about specific FDA-unapproved drug uses. This new guide to the literature will enable the health care professional/clinician to quickly identify published studies on off-label uses and to determine if a specific use is rational in a patient care scenario. The most relevant data are provided in tabular form so that the reader can easily identify the scope of information available. A summary of the data–including, background, study design, patient population, dosage information, therapy duration, results, safety, and therapeutic considerations–precedes each table of published studies. References direct the reader to the full literature for more comprehensive information prior to patient care decisions. Direct questions or comments on “Off-Label Drug Uses” to hospitalpharmacy@drugfacts.com .
Fondaparinux Sodium
Authors: Cada Dennis J. , Levien Terri , Baker Danial E. 
Published: January 2018

Each month, subscribers to The Formulary®Monograph Service receive five to six well-documented monographs on drugs that are newly released or are in late Phase III trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation (DUE) is also provided each month. The monographs are published in printed form and on diskettes that allow customization. Subscribers to the The Formulary Monograph Service also receive access to a pharmacy bulletin board, The Formulary Information Exchange (The F.I.X). All topics pertinent to clinical and hospital pharmacy are discussed on The F.I.X. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. If you would like information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800-322-4349. The July 2002 Formulary monograph topics are olmesartan medoximil, fulvestrant, adalimumab, secretin, and duloxetine. The DUE is on olmesartan medoximil.
USP-Proposed Changes in Neuromuscular Blocker Package Labeling Will Help Prevent Errors; Important Check: Why Are “Missing Doses” Missing?; Information Technology Department Has Important Role in Preventing Medication Errors; Caution about Name Similarity: Avinza and Invanz
Authors: Cohen Michael R. 
Published: January 2018

These medication errors have occurred in health care facilities at least once. They will happen again–perhaps where you work. Through education and alertness of personnel and procedural safeguards, they can be avoided. You should consider publishing accounts of errors in your newsletters and/or presenting them in your inservice training programs. Your assistance is required to continue this feature. The reports described here were received through the USP Medication Errors Reporting Program, which is presented in cooperation with the Institute for Safe Medication Practices. If you have encountered medication errors and would like to report them, you may call USP toll-free, 24 hours a day, at 800-233-7767 (800-23-ERROR). Any reports published by ISMP will be anonymous. Comments are also invited; the writers' names will be published if desired. ISMP may be contacted at the address shown below.
Pegfilgrastim
Authors: Cada Dennis J. , Levien Terri , Baker Danial E. 
Published: January 2018

Each month, subscribers to The Formulary® Monograph Service receive five to six well-documented monographs on drugs that are newly released or are in late Phase III trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation (DUE) is also provided each month. The monographs are published in printed form and on diskettes that allow customization. Subscribers to the The Formulary Monograph Service also receive access to a pharmacy bulletin board, The Formulary Information Exchange (The F.I.X). All topics pertinent to clinical and hospital pharmacy are discussed on The F.I.X. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. If you would like information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800-322-4349. The July 2002 Formulary monograph topics are voriconazole, treprostinil sodium injection, ranolazine, alefacept, and pregabalin. The DUE is on voriconazole.
More on Avoiding Opiate Toxicity with PCA by Proxy; Brand Name Arixtra (Fondaparinux) Confused with Laboratory Test for Anti-Factor Xa; Avoid “AD” as an Abbreviation for “Right Ear”
Authors: Cohen Michael R. 
Published: January 2018

These medication errors have occurred in health care facilities at least once. They will happen again–perhaps where you work. Through education and alertness of personnel and procedural safeguards, they can be avoided. You should consider publishing accounts of errors in your newsletters and/or presenting them in your inservice training programs. Your assistance is required to continue this feature. The reports described here were received through the USP Medication Errors Reporting Program, which is presented in cooperation with the Institute for Safe Medication Practices. If you have encountered medication errors and would like to report them, you may call USP toll-free, 24 hours a day, at 800-233-7767 (800-23-ERROR). Any reports published by ISMP will be anonymous. Comments are also invited; the writers' names will be published if desired. ISMP may be contacted at the address shown below.
Knowledge of Hospital Acquisition Costs of Antibiotics among Physicians in a Community Hospital
Authors: Schroeder Sara L. , Dobesh Paul P. , Abu-Shanab Joy R. , Lakamp Jonathan E. 
Published: January 2018

Purpose Cost-conscious prescribing requires that physicians be knowledgeable about drug costs. A cost card was used as the primary method of educating physicians about antibiotic costs in this facility. A survey was conducted to determine physicians' knowledge of the acquisition costs of antibiotics and to assess the effectiveness of the cost card as an educational tool. Methods Surveys were sent to 433 physicians in the departments of medicine and surgery. Physicians were asked to designate a hospital cost range for 25 antibiotics on formulary. Percentages of correct responses were determined for all antibiotics. Physicians were also asked a series of questions about their sources of drug cost information and whether they believed that this information was sufficient. Results The average percentage of correct answers to the antibiotic cost questions was 31.7%. Of physicians surveyed, 53% felt that they did not receive enough information regarding drug costs and 57% felt that it would be helpful to have more frequent cost updates. Conclusions Despite efforts to provide antibiotic cost information via a cost card, physicians for the most part are not cognizant of antibiotic costs. Physicians are aware that they lack knowledge about the cost of these drugs and desire further information and education. Educational initiatives will be implemented to facilitate cost-conscious prescribing.
Interferon Beta-1a
Authors: Cada Dennis J. , Levien Terri , Baker Danial E. 
Published: January 2018

Each month, subscribers to The Formulary® Monograph Service receive five to six well-documented monographs on drugs that are newly released or are in late Phase III trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation (DUE) is also provided each month. The monographs are published in printed form and on diskettes that allow customization. Subscribers to the The Formulary Monograph Service also receive access to a pharmacy bulletin board, The Formulary Information Exchange (The F.I.X.). All topics pertinent to clinical and hospital pharmacy are discussed on The F.I.X. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. If you would like information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800-322-4349. The September 2002 Formulary monograph topics are ziprasidone mesylate for injection; lanthanum carbonate, artesunate rectal capsules, ZD1839, and memantine. The DUE is on ziprasidone.
Ensure Proper Mixing of Dual-Chamber Bags; Do Recruiters and Telemarketers Contribute to Dispensing Errors?; Wrong Dose Recognized, Not Returned, and Eventually Administered; Pediatric Medication Error Prevention Guidelines Published by ISMP and PPAG; Nonproprietary Names Also Involved in Errors
Authors: Cohen Michael R. 
Published: January 2018

These medication errors have occurred in health care facilities at least once. They will happen again–perhaps where you work. Through education and alertness of personnel and procedural safeguards, they can be avoided. You should consider publishing accounts of errors in your newsletters and/or presenting them in your inservice training programs. Your assistance is required to continue this feature. The reports described here were received through the USP Medication Errors Reporting Program, which is presented in cooperation with the Institute for Safe Medication Practices. If you have encountered medication errors and would like to report them, you may call USP toll-free, 24 hours a day, at 800-233-7767 (800-23-ERROR). Any reports published by ISMP will be anonymous. Comments are also invited; the writers' names will be published if desired. ISMP may be contacted at the address shown below.
Gabapentin: Hot Flashes
Authors: Generali Joyce , Cada Dennis J. 
Published: January 2018

Off-Label Drug Uses This Hospital Pharmacy feature is extracted from Off-Label DrugFacts, a quarterly publication available from Facts and Comparisons. Off-Label DrugFacts is a practitioner-oriented resource for information about specific FDA-unapproved drug uses. This new guide to the literature will enable the health care professional/clinician to quickly identify published studies on off-label uses and to determine if a specific use is rational in a patient care scenario. The most relevant data are provided in tabular form so that the reader can easily identify the scope of information available. A summary of the data–including, background, study design, patient population, dosage information, therapy duration, results, safety, and therapeutic considerations–precedes each table of published studies. References direct the reader to the full literature for more comprehensive information prior to patient care decisions. Direct questions or comments on “Off-Label Drug Uses” to hospitalpharmacy@drugfacts.com .
The Use of Metoclopramide in Ileus: A Look at Duration of Therapy
Authors: Bolesta Scott , Erstad Brian L. 
Published: January 2018

Purpose The authors conducted a retrospective chart review to determine if metoclopramide was being used properly for ileus and if it caused any adverse effects. Methods All adult patients admitted to the institution's ICUs between November 10, 2000 and January 31, 2001 were evaluated for enrollment. Data was obtained from medication administration records, patient flow sheets, the computer-based laboratory and report systems, and a database of adverse drug events. Bowel movements were used to assess effectiveness. The primary end-point was the length of time metoclopramide was continued after the first bowel movement. A secondary endpoint was the occurrence of any adverse effects related to metoclopramide administration. Results There were a total of 32 patients who received metoclopramide for ileus during the time period studied. The average number of days people received metoclopramide was 11.5 ± 7.3 days. The mean time to first bowel movement was 1.7 ± 1.4 days. Patients had therapy continued after first bowel movement for an average of 10.7 ± 7.1 days. Extrapyramidal symptoms possibly occurred in 3% of the patients. Conclusion The results suggest that metoclopramide was used for the treatment of ileus in ICU patients for prolonged periods of time. This overuse may place patients at risk for adverse events and may also occur at other institutions.
Voriconazole
Authors: Cada Dennis J , Levien Terri , Baker Danial E. 
Published: January 2018

Each month, subscribers to The Formulary Monograph Service receive five to six well-documented monographs on drugs that are newly released or are in late Phase III trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and pharmacy/nursing in-ser-vices. A comprehensive target drug utilization evaluation (DUE) is also provided each month. The monographs are published in printed form and on diskettes that allow customization. Subscribers to the The Formulary Monograph Service also receive access to a pharmacy bulletin board, The Formulary Information Exchange (The F.I.X.). All topics pertinent to clinical and hospital pharmacy are discussed on The F.I.X. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. If you would like information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800-322-4349. The September 2002 monograph topics are ziprasidone mesylate for injection; lanthanum carbonate, artesunate rectal capsules, ZD1839, and memantine. The DUE is on ziprasidone.
Check Crash Cart Drug Concentrations for Broselow Tape Compatibility; Different Dosage Forms of Same Drug May Not Share the Same Monograph in the PDR; Mifepristone Confused with Misoprostol; A Nurse “Nose” How to Differentiate Products
Authors: Cohen Michael R. 
Published: January 2018

These medication errors have occurred in health care facilities at least once. They will happen again–perhaps where you work. Through education and alertness of personnel and procedural safeguards, they can be avoided. You should consider publishing accounts of errors in your newsletters and/or presenting them in your inservice training programs. Your assistance is required to continue this feature. The reports described here were received through the USP Medication Errors Reporting Program, which is presented in cooperation with the Institute for Safe Medication Practices. If you have encountered medication errors and would like to report them, you may call USP toll-free, 24 hours a day, at 800-233-7767 (800-23-ERROR). Any reports published by ISMP will be anonymous. Comments are also invited; the writers' names will be published if desired. ISMP may be contacted at the address shown below.
Treprostinil Sodium Injection
Authors: Cada Dennis J. , Levien Terri , Baker Danial E. 
Published: January 2018

Each month, subscribers to The Formulary Monograph Service receive five to six well-documented monographs on drugs that are newly released or are in late Phase III trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation (DUE) is also provided each month. The monographs are published in printed form and on diskettes that allow customization. Subscribers to the The Formulary Monograph Service also receive access to a pharmacy bulletin board, The Formulary Information Exchange (The F.I.X.). All topics pertinent to clinical and hospital pharmacy are discussed on The F.I.X. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. If you would like information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800-322-4349. The November 2002 monograph topics are adefovir dipivoxil, ximelagatran, agalsidase alfa and agalsidase beta, pemetrexed, and emtricitabine. The DUE is on adefovir dipivoxil.
Developing a Web-Based Tool Using Hospital-Specific Cumulative Antibiogram Data
Authors: Ting Yee-Way , Miles Donald 
Published: January 2018

Objective To develop new methods of using hospital-specific antibiograms. Methods An electronic database of the results of hospital-specific antibiograms from 1989 to 2001 was constructed. To aid clinicians in selecting empiric treatment for infection, a table of antibiotics of choice with assigned values to corresponding pathogens was derived from the database. A searchable version of the database was also created and installed on the hospital's Web site, as a resource for clinicians. Users may view the data online or download it in personal digital assistant (PDA) format. Results The table of antibiotics of choice and the searchable database became available on our hospital Web site, at http://www.sfmc.net/services/allServices/Pharmacy/inpatientPharmacy.html . Conclusion This article describes a novel way of using hospital-specific antibiogram data. Beyond spot viewing of a year-long antibiogram, the long-term trends revealed by the database should provide a more in-depth resource for clinicians selecting empiric therapy for infectious diseases. It is hoped that placing this information on the Internet and making it accessible on a PDA will increase the utility of local microbiological data.
Use Your Preadmission Process to Enhance Safety;Beware of Drug Names that End in the Letter “L”; It Doesn't Pay to Play the Percentages
Authors: Cohen Michael R. 
Published: January 2018

These medication errors have occurred in health care facilities at least once. They will happen again—perhaps where you work. Through education and alertness of personnel and procedural safeguards, they can be avoided. You should consider publishing accounts of errors in your newsletters and/or presenting them in your inservice training programs. Your assistance is required to continue this feature. The reports described here were received through the USP Medication Errors Reporting Program, which is presented in cooperation with the Institute for Safe Medication Practices. If you have encountered medication errors and would like to report them, you may call USP toll-free, 24 hours a day, at 800–233–7767 (800–23-ERROR). Any reports published by ISMP will be anonymous. Comments are also invited; the writers' names will be published if desired. ISMP may be contacted at the address shown below.
Metformin: Weight Loss (Antipsychotic–Induced Weight Gain)
Authors: Generali Joyce , Cada Dennis J. 
Published: January 2018

Off-Label Drug Uses This Hospital Pharmacy feature is extracted from Off-Label DrugFacts, a quarterly publication available from Facts and Comparisons. Off-Label DrugFacts is a practitioner-oriented resource for information about specific FDA-unapproved drug uses. This new guide to the literature will enable the health care professional/clinician to quickly identify published studies on off-label uses and to determine if a specific use is rational in a patient care scenario. The most relevant data are provided in tabular form so that the reader can easily identify the scope of information available. A summary of the data—including, background, study design, patient population, dosage information, therapy duration, results, safety, and therapeutic considerations—precedes each table of published studies. References direct the reader to the full literature for more comprehensive information prior to patient care decisions. Direct questions or comments on “Off-Label Drug Uses” to hospitalpharmacy@drugfacts.com .